Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Report Summary

Result	Low Risk
Fetal DNA Fraction	17.56%

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Report Details

Prenatal Aneuploidy Test Results of Chromosome 13, 18 and 21

Chromosome	Risk	Test Results	Z score
Chromosome 13	🟢	Low Risk	-0.21
Chromosome 18	🟢	Low Risk	-0.86
Chromosome 21	🟢	Low Risk	-0.74

※ Risk description: 🟢Low risk (< 1/10000); 🔴High risk (1/20)

COMMENTS:

Prenatal Aneuploidy Test Results of Sex Chromosomes

Sex Chromosome Aneuploidies	Risk	Test Results	Z score
XO	🟢	Low Risk	
XXY/XYY	🟢	Low Risk	0.22
XXX	🟢	Low Risk	

FETAL SEX DETERMINATION IS NOT POSSIBLE

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Prenatal Aneuploidy Test Results of Other Chromosomes

Chromosome	Risk	Test Results	Z score
Chromosome 1		Low Risk	1.82
Chromosome 2		Low Risk	1.99
Chromosome 3		Low Risk	0.14
Chromosome 4		Low Risk	-1.23
Chromosome 5		Low Risk	-1.25
Chromosome 6		Low Risk	0.72
Chromosome 7		Low Risk	-0.35
Chromosome 8		Low Risk	-1.45
Chromosome 9		Low Risk	-1.30
Chromosome 10		Low Risk	-0.09
Chromosome 11		Low Risk	0.34
Chromosome 12		Low Risk	0.11

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Chromosome 14		Low Risk	1.03
Chromosome 15		Low Risk	0.49
Chromosome 16		Low Risk	-0.15
Chromosome 17		Low Risk	-2.49
Chromosome 19		Low Risk	0.71
Chromosome 20		Low Risk	-2.49
Chromosome 22		Low Risk	2.39

※ Risk description: Low risk group; High risk group

COMMENTS:

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Methodology

NIPT screens a maternal blood sample for chromosome aneuploidy in fetal DNA using the following methodology:
(1) Extraction of cell-free fetal DNA from the anti-coagulated 10mL maternal blood sample
(2) High throughput sequencing of the extracted cell-free fetal DNA
(3) Calculation of molecular mass of fetal DNA in all chromosomes

Based on the scope, the NIPT test can detect the following:
(A) Whole Genome - Human Chromosomes
(B) Common Chromosomal Abnormality:
- Trisomy 13 (Patau's Syndrome)
- Trisomy 18 (Edward's Syndrome)
- Trisomy 21 (Down's Syndrome)
- Sex Chromosomal Aneuploidies

The test is capable of genome-wide aneuploidy detection over the whole fetal genome (23 pairs of chromosomes) and offers an interpretation of the results for trisomy 13, trisomy 18 and trisomy 21.

Analytical Sensitivity

This test confers an accuracy of up to 99% on the detection of fetal chromosome aneuploidy.

	Specificity	FPR	Sensitivity	FNR
T21	>99.99%	<0.001%	98.73%	1.27%
T13	99.98%	0.02%	>99.99%	<0.001%
T18	99.97%	0.02%	>99.99%	<0.001%
SCAs	99.98%	0.02%	97.78%	2.22%

Z-score Reference Range

Chromosome 13; 18; 21	Z-score ≥ 3.5	3.5 > Z-score ≥ 2.8	2.8 > Z-score > -6	Z-score ≤ -6
	Trisomy	Trisomy Borderline	Low Risk	Monosomy High Risk
Other Chromosomes and negative for Chr 13, 18, 21	Z-score ≥ 6	6 > Z-score > -6	Z-score ≤ -6	
	Trisomy High Risk	Low Risk	Monosomy High Risk	

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

Limitation / Disclaimer

- NIPT screens for chromosomal aneuploidies of the fetus after 10 weeks of gestation in singleton and twin pregnancies.
- Pregnant women with a positive test result should be referred to genetic counselling and offered an invasive prenatal diagnosis for confirmation of the test result.
- A negative test result do not ensure an unaffected pregnancy.
- While results of this testing are highly accurate, not all chromosomal abnormalities may be detected due to placental, maternal or fetal mosaicism, or other causes (micro-deletions, chromosome re-arrangements, translocations, inversions, unbalanced translocations, uniparental disomy).
- Test results can be confounded by maternal and/or fetal factors like recent maternal blood transfusion, maternal organ transplant, surgical procedure, maternal malignancy, immunotherapy or stem cell therapy, fetal demise, disappearing/vanishing twin, fetal partial trisomy or partial monosomy. This test does not detect polyploidy such as triploidy and balanced translocation.
- Only samples collected in the kit provided by HaystackAnalytics will be accepted.
- In some cases, sample recollection may be requested based on technical limitations in order to provide a result.
- Despite taking all necessary precautions, in rare cases, the test may not give correct result due to quality of the sample, or the test fails for unknown reasons which cannot be foreseen. In such circumstances, the company shall not be responsible for any incomplete, potentially misleading or incorrect results that were not foreseeable beforehand.
- Although the turn-around- time (TAT) timeframe is accounted from the time of receipt of sample in the lab, the actual TAT may differ based on the complexity of the requested test(s) and information provided along with the sample. HaystackAnalytics Pvt. Ltd. shall not be responsible for delays caused due to incomplete information and or any technical requirements during sample handing over/testing/reporting.
- The information contained in this report, should not be considered an alternative for professional medical advice or diagnosis. It is imperative that the healthcare provider interprets and explains the test results to the patients and further recommendations should also be suggested. Clinical interpretation of given test result should be evaluated taking into account the parents' medical history and other diagnostic laboratory test results.

Notes:

- This test has been validated and its performance characteristics are determined in accordance with the CAP/ACMG and NABL guidelines in an accredited laboratory.
- As per the PRE-NATAL DIAGNOSTIC TECHNIQUES (REGULATIONS & PREVENTION OF MISUSE) AMENDMENT ACT 2002, sex determination shall not be done for all prenatal samples.

Patient Name	Vidya Jadhav	**Patient ID**	VIDYF1410922
Age/Gender	34/F	**Sample ID**	NIPTMUM112102603
Ref Doctor	Dr. Ashok Majji	**Collection Date**	12-October-2026
Received Date	12-October-2026	**Reporting Date**	22-October-2026
Address	Mumbai	**Test Name**	NIPT
Gestational Period	13 WEEKS 5 DAYS	**Type of Pregnancy**	SINGLETON

References

- The American College of Obstetrics and Gynecology. Policy priorities. https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance
- Eur Rev Med Pharmacol Sci. 2023;27(15):7101-7106. doi: 10.26355/eurrev_202308_33283.
- Ann Transl Med. 2023;11(2):111. doi: 10.21037/atm-22-6343
- Genetics in Medicine. 2023; 25: 100874. doi: 10.1016/j.gim.2023.100874.

Dr. Amrutraj Zade
Head - R&D,
HaystackAnalytics Pvt. Ltd

Dr. Aparna Bhanushali, PhD
Director - Medical Genetics,
European Board Certified
Clinical Laboratory
Geneticist (affiliated)